<DOC>
	<DOCNO>NCT00326625</DOCNO>
	<brief_summary>Teva develop 40 mg/ml Glatiramer Acetate ( GA ) Injection , administer daily skin , treatment ALS . The study drug high dose formulation CopaxoneÂ® ( 20 mg/ml GA ) , market medication , approve treatment relapsing-remitting multiple sclerosis . GA immunomodulating drug anti inflammatory neuroprotective property , believe therapeutic value ALS . The study treatment duration 1 year ( 52 week ) .</brief_summary>
	<brief_title>Clinical Trial Glatiramer Acetate Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Diagnosis definite probable ALS accordance ElEscorial criterion . 2 . Subject experience his/her first ALS symptom within 3 year prior screen visit . 3 . Slow VC test equal great 70 % predict value . 4 . The sum 3 respiratory item ALSFRSR must total least 10 point . 5 . Stable dose riluzole least 8 week prior screen . 6 . Age 1870 ( inclusive ) . 1 . The use invasive noninvasive ventilation . 2 . Subject undergone gastrostomy . 3 . Subject clinically significant unstable medical condition . 4 . Subjects participate clinical trial ( within 12 week prior screen thereafter ) . 5 . Additional criterion per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>